vs

Side-by-side financial comparison of BlackSky Technology Inc. (BKSY) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $35.2M, roughly 1.0× BlackSky Technology Inc.). BlackSky Technology Inc. runs the higher net margin — -2.5% vs -304.2%, a 301.8% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 15.9%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 20.5%).

BlackSky Technology Inc. is a leading geospatial intelligence provider operating a constellation of high-revisit small Earth observation satellites. It delivers real-time satellite imagery, advanced data analytics, and dynamic monitoring solutions to government, defense, critical infrastructure, and commercial clients globally to support data-driven operational decision-making.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

BKSY vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.0× larger
RXRX
$35.5M
$35.2M
BKSY
Growing faster (revenue YoY)
RXRX
RXRX
+665.8% gap
RXRX
681.7%
15.9%
BKSY
Higher net margin
BKSY
BKSY
301.8% more per $
BKSY
-2.5%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
20.5%
BKSY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BKSY
BKSY
RXRX
RXRX
Revenue
$35.2M
$35.5M
Net Profit
$-868.0K
$-108.1M
Gross Margin
59.8%
Operating Margin
-11.8%
-304.8%
Net Margin
-2.5%
-304.2%
Revenue YoY
15.9%
681.7%
Net Profit YoY
95.5%
39.6%
EPS (diluted)
$0.04
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BKSY
BKSY
RXRX
RXRX
Q4 25
$35.2M
$35.5M
Q3 25
$19.6M
$5.2M
Q2 25
$22.2M
$19.2M
Q1 25
$29.5M
$14.7M
Q4 24
$30.4M
$4.5M
Q3 24
$22.5M
$26.1M
Q2 24
$24.9M
$14.4M
Q1 24
$24.2M
$13.8M
Net Profit
BKSY
BKSY
RXRX
RXRX
Q4 25
$-868.0K
$-108.1M
Q3 25
$-15.3M
$-162.3M
Q2 25
$-41.2M
$-171.9M
Q1 25
$-12.8M
$-202.5M
Q4 24
$-19.4M
$-178.9M
Q3 24
$-12.6M
$-95.8M
Q2 24
$-9.4M
$-97.5M
Q1 24
$-15.8M
$-91.4M
Gross Margin
BKSY
BKSY
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
BKSY
BKSY
RXRX
RXRX
Q4 25
-11.8%
-304.8%
Q3 25
-85.8%
-3327.6%
Q2 25
-62.8%
-916.8%
Q1 25
-40.5%
-1297.9%
Q4 24
-20.0%
-4042.4%
Q3 24
-58.7%
-377.1%
Q2 24
-47.0%
-697.4%
Q1 24
-54.7%
-698.4%
Net Margin
BKSY
BKSY
RXRX
RXRX
Q4 25
-2.5%
-304.2%
Q3 25
-78.2%
-3135.3%
Q2 25
-185.8%
-894.2%
Q1 25
-43.4%
-1373.3%
Q4 24
-63.9%
-3935.5%
Q3 24
-55.8%
-367.5%
Q2 24
-37.7%
-676.6%
Q1 24
-65.2%
-662.4%
EPS (diluted)
BKSY
BKSY
RXRX
RXRX
Q4 25
$0.04
$-0.17
Q3 25
$-0.44
$-0.36
Q2 25
$-1.27
$-0.41
Q1 25
$-0.42
$-0.50
Q4 24
$-0.61
$-0.56
Q3 24
$-0.66
$-0.34
Q2 24
$-0.52
$-0.40
Q1 24
$-0.88
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BKSY
BKSY
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$124.5M
$743.3M
Total DebtLower is stronger
$201.1M
$9.6M
Stockholders' EquityBook value
$94.9M
$1.1B
Total Assets
$386.2M
$1.5B
Debt / EquityLower = less leverage
2.12×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BKSY
BKSY
RXRX
RXRX
Q4 25
$124.5M
$743.3M
Q3 25
$146.5M
$659.8M
Q2 25
$93.8M
$525.1M
Q1 25
$75.8M
$500.5M
Q4 24
$52.5M
$594.4M
Q3 24
$63.2M
$427.6M
Q2 24
$41.2M
$474.3M
Q1 24
$35.4M
$296.3M
Total Debt
BKSY
BKSY
RXRX
RXRX
Q4 25
$201.1M
$9.6M
Q3 25
$195.1M
$11.9M
Q2 25
$122.5M
$14.2M
Q1 25
$115.3M
$16.4M
Q4 24
$107.7M
$19.0M
Q3 24
$98.8M
$20.5M
Q2 24
$108.6M
$22.9M
Q1 24
$85.0M
Stockholders' Equity
BKSY
BKSY
RXRX
RXRX
Q4 25
$94.9M
$1.1B
Q3 25
$91.1M
$1.0B
Q2 25
$86.6M
$919.1M
Q1 25
$88.8M
$933.9M
Q4 24
$94.0M
$1.0B
Q3 24
$110.3M
$524.6M
Q2 24
$76.5M
$584.4M
Q1 24
$81.7M
$401.2M
Total Assets
BKSY
BKSY
RXRX
RXRX
Q4 25
$386.2M
$1.5B
Q3 25
$380.9M
$1.4B
Q2 25
$310.8M
$1.3B
Q1 25
$284.9M
$1.3B
Q4 24
$254.1M
$1.4B
Q3 24
$245.5M
$726.5M
Q2 24
$224.3M
$775.9M
Q1 24
$210.1M
$557.8M
Debt / Equity
BKSY
BKSY
RXRX
RXRX
Q4 25
2.12×
0.01×
Q3 25
2.14×
0.01×
Q2 25
1.41×
0.02×
Q1 25
1.30×
0.02×
Q4 24
1.15×
0.02×
Q3 24
0.90×
0.04×
Q2 24
1.42×
0.04×
Q1 24
1.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BKSY
BKSY
RXRX
RXRX
Operating Cash FlowLast quarter
$-9.3M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BKSY
BKSY
RXRX
RXRX
Q4 25
$-9.3M
$-46.1M
Q3 25
$-39.0M
$-117.4M
Q2 25
$-7.3M
$-76.4M
Q1 25
$27.2M
$-132.0M
Q4 24
$-1.8M
$-115.4M
Q3 24
$1.0M
$-59.2M
Q2 24
$-1.8M
$-82.2M
Q1 24
$-3.8M
$-102.3M
Free Cash Flow
BKSY
BKSY
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
BKSY
BKSY
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
BKSY
BKSY
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons